Welcome to The Weekly Skin Scan where our editors will keep you up-to-date on the latest news and research that could impact your practice. Browse more stories here.
Phase 3 data shows a novel gel formulation combining tretinoin 0.04% and clindamycin 1% using a controlled release microsphere delivery system effectively treats acne vulgaris without the skin irritation associated with topical tretinoin alone
A combination of ivermectin 1% cream and oral 40 mg doxycycline may be effective for some patients with moderate-to-severe rosacea, according to phase 3b/4 data.
The oral selective JAK inhibitor baricitinib may be an effective, safe option for patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 clinical trials.
A new systemic medication option offers promising results for patients with high-risk squamous cell carcinoma for whom surgery has not worked, according to Chrysalyne Schmults, M.D.
